News

Lantern Pharma outlines commercialization of RADR AI modules and expects LP-184 trial enrollment completion by June 2025

Lantern Pharma (LTRN) Gets FDA Clearance for Clinical Trial Targeting Treatment-Resistant, Genomically-Defined Lung Cancer with AI developed LP-184

Lantern to Test AI-Developed Drug in Triple- Negative Breast Cancer Trial

Lantern Pharma Advances AI-Guided Drug into Phase 1b/2 Trial for Triple Negative Breast Cancer

Lantern Pharma (LTRN) Gets FDA Green Light to Begin Human Trials for New Breast Cancer Drug

World Cancer Day: Innovation in the Cancer Treatment Pipeline

Lantern Pharma Unveils AI Module to Enhance ADC Cancer Development

Lantern says AI-powered platform can find new ADC targets and payloads

Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back

Breakthrough with AI-Powered Drug LP-300 in Lung Cancer Treatment

FDA Grants Fast Track Designation to LP-184 for Glioblastoma

AI is helping researchers fast-track discovering life-saving drugs

Lung Cancer Treatment for Never Smokers: The HARMONIC Phase 2 Trial and LP-300

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

LP-300 Shows Promise in Treating Advanced Lung Cancer in Never Smokers

LP-300 Plus Chemo Yields Early Efficacy Results in Never-Smokers With NSCLC

How AI is transforming drug discovery

Behind the powerful computations, AI’s role in pharma is still beset by challenges

Lantern Pharma's Pioneering Role in AI-Driven Oncology Drug Development with the RADR® Platform

Putting LP-284 on the Industry RADR

Lantern Pharma is harnessing the power of AI and Machine Learning to Fight Cancer

How Lantern Pharma’s AI Is Changing the Game

Lantern Pharma aims to take drug to phase 3 for $100-200 million with AI-powered approach

Lantern Pharma Targets Surprising Group For Lung Cancer Screenings

The trends that will shape the biotech industry in 2024

Navigating the Crossroads of AI and Oncology: A Deep Dive with Lantern Pharma's CEO, Panna Sharma

FDA Grants Orphan Drug Designation to LP-284 for Treatment of HGBL With MYC, BCL2 Rearrangements

FDA Grants Orphan Drug Designation to LP-284 for High-Grade B-Cell Lymphomas

How Lantern Pharma and Code Ocean partnered on oncology drug development

Building a Path to Cure for Patients With NSCLC Who Have Never Smoked

Lantern Pharma doses first patient in solid tumour drug trial

9 Notable AI Companies in Clinical Research to Watch in 2023

AI Breaches the Barrier Towards Better CNS Drug Discovery

Dallas firm’s experimental cancer drug set to begin human trials this summer

Using AI in the Development of Novel ADCs: Lantern Pharma and Bielefeld University to Cooperate

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Unveiling Lantern Pharma's Success Story in AI-powered Precision Oncology

Lantern Pharma Offers AI Platform for ADC Discovery with Bielefeld University

Lantern Pharma to Study LP-184 in DNA Damage Response-Deficient Solid Tumors

Lantern Pharma launches a cutting-edge AI algorithm

Busting the Brain’s Firewall: How Lantern Pharma’s Algorithms Can Predict a Drug’s Ability to Reach the Brain

Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

LP-284 Exhibits Preclinical Efficacy in DDR-Deficient MCL

Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise

BPT20: Artificial Intelligence in Drug Discovery Productivity Index

Powering Cancer Drug Discovery and Development Using the Artificial Intelligence and Machine Learning Platform RADR®

LP-284 Shows Preclinical Activity in ATM-Mutated MCL

Lantern Pharma releases positive Preclinical Data on Efficacy of LP-284 for Mantle Cell Lymphoma

Highs and lows of drug repurposing

Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer

Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate

Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA

Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC

Lantern Pharma: transforming oncology drug development with AI

Nearly 300 Novel Agents Currently in Development for Rare Cancers

This Pharma Company Is Using Machine Learning And AI To Attempt To Transform Oncology Drug Development Processes

Lantern Pharma is Using Artificial Intelligence to Develop Oncology Treatments

Episode 703: Panna Sharma on Leveraging Artificial Intelligence To Rescue and Develop Cancer Therapies

Action & Ambition Podcast

Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT)

Lantern Pharma Collaborating With Danish Cancer Research Center on Drugs for NER-Deficient Tumors

Lantern Pharma and NCI expand oncology partnership

Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates

Lantern Pharma (LTRN) Reports Positive Efficacy Data of LP-284 in Hematologic Cancers

What is the Real Cost of Developing Medicine?

Healthcare Americana Podcast

Cost of Care: Defanged drug pricing reform means less of a bite for Big Pharma

The Local Oncology Innovator ‘Smashing’ Drug Development Timelines

Why we are on the cusp of a golden age of medicine

The AI Pharmacist: How Artificial Intelligence Can Accelerate Drug Development

Slice of Healthcare Podcast #192 – Panna Sharma, CEO & President at Lantern Pharma

How Technologies Like AI and Machine Learning Can Help With the Development of Medicine

TradeTalks Video Broadcasts - With Jill Malandrino

BioBoss Podcast #39 - Panna Sharma, CEO of Lantern Pharma

Biotech is sprouting into Dallas-Fort Worth’s next big thing, based on seeds planted decades ago

Join our team and help transform the cancer drug development process, cost and timeline!

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

Lantern Pharma CEO Shares His Four Secrets to Turning a Startup into an IPO

Benzinga's Power Hour Show

How AI Is Expediting Medicine Development

Allarity Therapeutics, Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

Dallas region sees growing traction around the life sciences amid IPOs, fundings

Midday Hot Stocks: SPCE falls as Bezos flies; HAL, UBS rise on earnings; LTRN gets strong pre-clinical data

Preclinical Data on New Pancreatic Cancer Drug Shines with over 90% Efficacy

How AI Is Transforming the Healthcare Landscape & Accelerating the Development of Medicine

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern’s Artificial Intelligence Platform

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company’s Progress in the Development of Biopharma Collaborations and Partnerships and Advancing

New Lantern Manuscript: The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations

Lantern ($LTRN) Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with

A machine learning‐based gene signature of response to the novel alkylating agent LP‐184 distinguishes its potential tumor indications

Technology Is Rapidly Changing Cancer Care

AI offers promise but faces barriers in drug development

Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development

Episode 68: Rocking Garage Biotech

What going public means for Lantern Pharma

Lantern Pharma, Fox Chase Partner on Pancreatic Cancer Drug, Search for Predictive Gene Signature